LIS Consulting – Regulatory Affairs Experts in Dubai for MENA & Europe

As a trusted partner for regulatory affairs services in the UAE, we deliver end-to-end solutions including:

• Medical device registration in GCC countries
• CE marking and European regulatory compliance
• In-vitro diagnostic device approvals
• Personal care product compliance
• Technical documentation, GSPR, and dossier preparation
• Regulatory strategy and market entry planning

LIS Consulting (LIS) is a Dubai-based regulatory affairs consultancy specializing in healthcare compliance and market access across the MENA region and Europe. Founded in 2021 and headquartered in the United Arab Emirates, we help medical device manufacturers, in-vitro diagnostic (IVD) companies, and personal care brands achieve regulatory approval and expand into new markets.

LIS Consulting is proudly a member of the Dubai Chamber of Commerce (Membership No. DSO-FZCO-7648), reinforcing our strong ties with the UAE healthcare and business ecosystem.

Our team of seasoned regulatory affairs consultants offers tailored services and flexible engagement models, including remote support and dedicated back-office operations to ensure rapid and efficient project delivery.

Regulatory Affairs Support for MENA and Europe

LIS Consulting operates as a consortium of expert consultancy firms specializing in regulatory affairs for medical devices and healthcare products. We serve as a reliable regulatory partner to global manufacturers aiming to access markets across the Middle East, North Africa, and Europe.

We work closely with regulatory authorities in the MENA region, including:

• Ministry of Health and Prevention (MoHAP) – UAE
• Saudi Food & Drug Authority (SFDA)
• Jordan Food & Drug Administration (JFDA)
• Egyptian Drug Authority (EDA)
• Qatar Ministry of Public Health
• Notified Bodies in Europe for CE marking

Our proven expertise in local and international regulatory frameworks makes LIS Consulting the go-to firm for fast, compliant, and strategic healthcare market access.